<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512745</url>
  </required_header>
  <id_info>
    <org_study_id>HENGRUI 20101208</org_study_id>
    <nct_id>NCT01512745</nct_id>
  </id_info>
  <brief_title>Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer</brief_title>
  <official_title>A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 81 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor
      receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The
      investigators' phase I study has shown that the drug's toxicity is manageable and the maximum
      tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib
      can improve progression free survival or overall survival compared with placebo in patients
      with metastatic gastric carcinoma who failed two lines of chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>30 months</time_frame>
    <description>Overall Survival of the Participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>30 months</time_frame>
    <description>Disease control is defined as the proportion of patients who had a best response rating of complete response, partial response, or stable disease, and lasted at least 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>30 months</time_frame>
    <description>Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Advanced or Metastatic Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 and ≤ 70 years of age

          -  Histological confirmed advanced or metastatic adenocarcinoma of the stomach

          -  Have failed for at least 2 lines of chemotherapy

          -  Life expectancy of at least 12 weeks.

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1 within 1 week before
             randomization.

          -  At least one measurable lesion beyond stomach (larger than 10 mm in diameter by spiral
             CT scan)

          -  Duration from the last therapy is more than 6 weeks for nitroso or mitomycin

          -  More than 4 weeks for operation or radiotherapy

          -  More than 4 weeks for cytotoxic agents or growth inhibitors

          -  Adequate hepatic, renal, heart, and hematologic functions (HB ≥ 90g/L,platelets &gt; 80
             ×10 E+9/L, neutrophil &gt; 1.5 × 10 E+9/L, serum creatinine ≤ 1× upper limit of
             normal(ULN), bilirubin &lt; 1.25× ULN, and serum transaminase ≤ 2.5× ULN).

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix Hypertension and unable to be controlled within normal level
             following treatment of anti-hypertension agents (systolic blood pressure &gt; 140 mmHg,
             diastolic blood pressure &gt; 90 mmHg).

          -  Any factors that influence the usage of oral administration; Evidence of Central
             Nerves System(CNS) metastasis

          -  Intercurrence with one of the following: coronary artery disease, arrhythmia ,heart
             failure and proteinuria ≥ (+)

          -  International Normalize Ratio (INR) &gt; 1.5 and activated partial thromboplastin
             time（APPT） &gt; 1.5 × ULN

          -  Abuse of alcohol or drugs

          -  Certain possibility of gastric or intestine hemorrhage

          -  Less than 4 weeks from the last clinical trial

          -  Prior VEGFR inhibitor treatment

          -  Disability of serious uncontrolled intercurrence infection Objective evidence of
             previous or current pulmonary fibrosis history, interstitial pneumonia,
             Pneumoconiosis, radiation pneumonitis, drug-related pneumonia, Pulmonary function
             damaged seriously etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shukui Qin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 81 Hospital of PLA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The 81 Hosiptal of PLA</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University cancer hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <results_first_submitted>August 6, 2015</results_first_submitted>
  <results_first_submitted_qc>May 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2016</results_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Apatinib</title>
          <description>apatinib: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>5 participants in the apatinib group and 1 in the placebo group withdrew from the study before receiving the assigned treatments.As a result,267 randomly assigned participants were included in Full Analysis Set （FAS），with 176 assigned to the apatinib group and 91 assigned to the placeo group.</population>
      <group_list>
        <group group_id="B1">
          <title>Apatinib</title>
          <description>apatinib: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="267"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.01" spread="9.92"/>
                    <measurement group_id="B2" value="56.08" spread="9.74"/>
                    <measurement group_id="B3" value="55.37" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival(PFS)</title>
        <description>Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</description>
        <time_frame>30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apatinib</title>
            <description>apatinib: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival(PFS)</title>
          <description>Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</description>
          <units>month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.0" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.4" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival(OS)</title>
        <description>Overall Survival of the Participants</description>
        <time_frame>30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apatinib</title>
            <description>apatinib: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival(OS)</title>
          <description>Overall Survival of the Participants</description>
          <units>month</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.8" upper_limit="7.6"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.6" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate(DCR)</title>
        <description>Disease control is defined as the proportion of patients who had a best response rating of complete response, partial response, or stable disease, and lasted at least 4 weeks.</description>
        <time_frame>30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apatinib</title>
            <description>apatinib: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate(DCR)</title>
          <description>Disease control is defined as the proportion of patients who had a best response rating of complete response, partial response, or stable disease, and lasted at least 4 weeks.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.05"/>
                    <measurement group_id="O2" value="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate(ORR)</title>
        <description>Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR)</description>
        <time_frame>30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apatinib</title>
            <description>apatinib: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate(ORR)</title>
          <description>Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <time_frame>30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apatinib</title>
            <description>apatinib: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.30"/>
                    <measurement group_id="O2" value="90.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Apatinib</title>
          <description>apatinib: apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>bleeding</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="176"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="71" subjects_affected="71" subjects_at_risk="176"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="66" subjects_affected="66" subjects_at_risk="176"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="176"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="176"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="176"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="176"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="176"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated transaminase</sub_title>
                <counts group_id="E1" events="49" subjects_affected="49" subjects_at_risk="176"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="176"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ALP increased</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="176"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>elevated GGT</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="176"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>elevated LDH</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="176"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="176"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>hypoproteinemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="176"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="176"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hand-foot syndrome</sub_title>
                <counts group_id="E1" events="49" subjects_affected="49" subjects_at_risk="176"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="176"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Co-Director of Clinical Trials</name_or_title>
      <organization>Fudan University Shanghai Cancer Center, Shanghai; PLA Cancer Centre, The 81 Hospital of PLA, Nangjing</organization>
      <phone>021-64433755</phone>
      <email>fudanlijin@163.com,qinsk@csco.org.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

